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We describe the case of a 33-year-old male patient representing an NF of his left leg.
 After non-responding to established broad anti-infective treatment, the patient received immunoglobulin (IVIg).
 The presented case suggests that IVIg treatment of patients with NF might be considered in case of critically ill patients.a r t i c l e i n f o
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Introduction: Necrotizing fasciitis (NF) is an inﬂammatory disease of the soft tissue, which causes local
tissue destruction and can lead to lethal septic shock. The therapy consists of early surgical treatment of
the septic focus and an accompanying broad spectrum antibiotic therapy. Recent literature considers the
additional use of immunoglobulin therapy in severe soft skin and tissue infections.
Presentation of case: In this report, we describe the case of a 33-year-old male patient treated at a
university hospital intensive care unit because of an NF of his left leg. The patient rapidly developed a
complicated septic disease after a minor superﬁcial trauma. Despite intense microbiological diagnosis, no
causative pathogens were identiﬁed. After non-responding to established broad anti-infective treatment,
the patient received intravenous immunoglobulin, that rapidly improved his clinical condition.
Discussion: NF represents a disease processes, which is characterized by fulminant, widespread necrosis
of soft tissue, systemic toxicity, and high mortality (>30%). Beside the surgical debridement and broad
spectrum antibiotic therapy IVIg therapy might be an additional option in the treatment of NF. But the
current literature supporting the use of IVIG in NF is largely based on retrospective or case-controlled
studies, and only small randomized trials.
Conclusion: The demonstrated case suggests that IVIg treatment of patients with NF can be considered in
case of hemodynamic unstable, critically ill patients. Although randomized controlled trials are missing,
some patients might beneﬁt from diminishing hyperinﬂammation by immunoglobins.
© 2015 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Limited. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Necrotizing fasciitis (NF) is deﬁned as a rapidly expanding
infection of fascia and subcutaneous tissue [1]. In general, the NF
can occur ubiquitously in soft tissues, but most common areas of
expansion are the extremities and in particular the lower legs [2].siology and Intensive Care
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r Ltd on behalf of IJS Publishing GrEven trunk, abdomen, head, neck area, or anal region are often
infected after surgery [3]. Common triggers are trivial trauma,
burns, surgery, decubital ulcers, perirectal abscesses or Fournier's
gangrene [4]. Risk factors for NF include diabetes mellitus,
immunosuppression, malnutrition, age, intravenous drug misuse,
peripheral vascular disease, renal failure, malignancy, and obesity
[5]. Patients with NF usually present severe pain around the
affected area and signs of skin infection (erythema, swelling,
oedema, subcutaneous plaques, or surface nodes) [6]. These
physical ﬁndings may rapidly evolve into a haemorrhagic infarc-
tion of the subcutis, the fascia and the dermis with the formationoup Limited. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Left lower leg at day 3 after admission.
Fig. 2. CT Image at day 3 after admission showing lung oedema, pleural effusions,
compression atelectasis of both lower lung lobes, and dorsal superior lobes. Ventilated
areas showing focal and lobular oedema, and thickening of the interlobular septa.
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microbial (type 1) and monomicrobial (type 2) infections [7]. Type
1 are mixed infections caused by anaerobic bacteria and Strepto-
cocci mainly serogroup A. Among these, Staphylococcus aureus,
Bacteroides fragilis and anaerobic cocci are the most common
pathogens [8]. Type 2 infections are caused by Streptococcus pyo-
genes alone, or in association with S. aureus or Staphylococcus
epidermidis. Clostridial infections have been classiﬁed by some
authors as type 3 necrotizing soft tissue infections [9]. Laboratory
tests usually show pronounced leucocytosis associated with
acidosis, hypocalcaemia, and anaemia [10]. The detection of
pathogens should be established by blood cultures and biopsies of
the affected areas. The mortality of NF is, depending on the study,
up to 50% and is usually caused by a pronounced sepsis with sec-
ondary multi organ failure [11,12]. Because of the very rapid pro-
gression and high mortality, early diagnosis and effective therapy
are needed [11,13]. In addition to the surgical treatment of the
infection focus with repeated debridement of the affected area,
intravenous administration of broad-spectrum antibiotics should
be started early [2,13].
2. Presentation of case
A 33-year-old patient in good general health and nutritional
status (185 cm, 80 kg) suffered from a minor, superﬁcial injury on
his lower left leg, which he acquired during a ski vacation. The
patient had no pre-existing diseases and no signiﬁcant medical
history. Local self-treatment led to a deterioration of the wound
conditions. About 10 days after the initial trauma, the outpatient
visited the centre for general medicine, followed by the initiation of
an antibiotic therapy with oral Cefuroxime. Because of a progres-
sive clinical deterioration of thewound conditions with appearance
of an aching hematoma, he was admitted two days later to hospital
for surgical treatment of the hematoma. In the course of the next
ﬁve days, two further wound debridements and the application of a
vacuum-assisted closure were performed. The antibiotic therapy
was escalated to Clindamycin (3  600 mg/d) and Tazobactam
(3  4.5 g/d). Due to a recent clinical deterioration and the need for
advanced therapeutic measures nine days after admission, the
patient was transferred to a university hospital.
On hospital admission, the patient was awake, oriented and in
stable respiratory and circulatory condition. During the clinical
examination, his temperature was 37.2 C, his blood pressure was
171/85 mmHg, pulse 140 beats per minute, rhythmic and his initial
oxygen saturation checked by pulse oximetry was 95% in room air.
He was somnolent but easily aroused and on examination pre-
sented. Secondary ﬁndings in physical examination were severe
pain and swellings in both axillae and in both groins. A laboratory
evaluation revealed an increase in white blood cell (WBC) count
(23.1  103/mL; reference value 4.00 to 11.00  103/mL), and C-
reactive protein (CRP) 298.8 mg/dL (reference value 0.0e0.5 mg/
dL). On the day of admission and the day after admission, we
immediately performed surgical wound excisions with large
debridement in the infected area of the left lower leg (Fig. 1). Due
to international recommendations [14e16] and the current anti-
biotic guidelines at our hospitals intensive care unit (ICU),
empirical antibiotic therapy was changed to Meropenem
(4  1000 mg/d), Penicillin G (6x 5 Mega I.E./d) and Clindamycin
(3  600 mg/d).
For further diagnostics, tissue samples and swabs from all
infected areas were taken intraoperatively. Blood cultureswere also
taken at different time points. But no causative pathogen could be
identiﬁed. Because of further increased inﬂammation markers and
clinical deterioration, the anti-infective therapy was supplemented
by Levoﬂoxacin (2 500mg/d) and Daptomycin (1000mg loading-dose, 500 mg/d) for the coverage of methicillin-sensitive S. aureus
and atypical pathogens two days after hospital admission. Caspo-
fungin (70 mg loading-dose, 50 mg/d) was also added to cover
invasive fungal infections. On the third day after admission, a hole-
body computed tomography scan was performed. The result
showed a fasciitis of the left upper and lower leg, and a symmetrical
bilateral pulmonary oedema. Furthermore, bilateral pleural effu-
sions impressed with basal atelectasis and a generalized barrier
disruption. Because of a progredient lung oedema (Fig. 2) and
consecutive respiratory dysfunction the patient developed the
need for mechanical ventilation.
At day 4 after admission, an additional operational inspection
and large debridement of both axillae were performed. Addition-
ally, the left thigh was surgically explored and a fasciotomy was
performed. The intraoperative inspection of the left leg revealed a
signiﬁcant increase of the necrotic area. The microbiological ana-
lyses of the collected samples were all negative. Because of a pos-
itive serological evidence of Herpes simplex virus-I a therapy using
Acyclovir (6  250 mg/d) was initiated. The following microbio-
logical tests using polymerase chain reaction resulted in the
detection of Corynebacterium tuberculostearicum in the taken
wound swab, and Acinetobacter baumanii in wound swabs, tissue
biopsy, pleural-punctate and blood. A direct detection of pathogens
did not succeed at any time.
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tion we decided to initiate a therapy with cortisone (Hydrocorti-
sone 0.105 mg/kg/h) and intravenous immunoglobulin (IVIg,
Pentaglobin loading dose 0.38 g/kg, 0.19 g/kg/d for the next 5 days)
at the 5th day after admission. During this therapy, the aspect of
hyperinﬂammation was diminished, the general condition
improved and weaning from the respirator could be performed
after 6 days of therapy.
CRP, WBC and pro-calcitonin dropped over the next days, and
the need for hemodynamic support was signiﬁcantly reduced (e.g.
norepinephrine dose) (Fig. 3). At day 10, vacuum assisted wound
closure was used to improve the wound conditions of the left lower
leg and both axillae. 32 days after hospital admission, the patient
could be moved from the ICU to the primary care station. Local
wound conditions recovered and wounds were closed at day 39
using split-skin graft from the right thigh. At day 48 after hospital
admission, the patient left the hospital in good general condition.
During a follow-up examination, 6 month later, the patient was
healthy and we found sufﬁcient wound conditions.
3. Discussion
Necrotizing soft tissue infections (NSTI) represent a broad
spectrum of disease processes, which are characterized by fulmi-
nant, widespread necrosis of soft tissue, systemic toxicity, and high
mortality (>30%). Here, we describe a patient who suffered from an
NF. Despite intense microbiological diagnosis, no causative patho-
gens were identiﬁed. After surgical treatment, we started an
extended spectrum antimicrobial and supportive therapy, though
without clinical improvement. Several multidrug regimens have
been described in the literature. According to our internal guide-
lines, our initial empirical antibiotic treatment consists in a com-
bination of penicillin, carbapenem and clindamycin. Penicillin
should always be included in the treatment of NF in consideration
of possible group A Streptococci etiology [13e15]. Because of the
emergence of penicillin-resistant staphylococci, an additional
broad spectrum antibiotic, must be considered to provide adequate
cover [13,14]. According to the life threatening condition and or
local resistance proﬁle, we chose a carbapenem. The additional use
of clindamycin is also recommended to inhibit M protein and
exotoxin synthesis by group A Streptococcus, thus controlling the
inﬂammatory response [16]. The described antibiotic escalation
therapy was used because of the patients' rapid clinical deteriora-
tion and the lack of causative pathogens and reﬂects current rec-
ommendations for the antiinfective treatment of NF [9,13,14].Fig. 3. Laboratory characteristics and need for vasopressor-therapy. A: Absolute values of C
care unit treatment. The arrow indicates the initiation of immunogloblin treatment (IVIg). B
surrogate for the need for hemodynamic support during intensive care unit treatment. TheDespite extended empirical antibiotic therapy and large surgical
debridement, we found a progressive deterioration of the patients'
condition. Consequently, we decided to initiate an immunosup-
pressive therapy with IVIg and hydrocortisone. IVIg therapy in-
volves the administration of pooled IVIg from human donors.
Regarding its broad range of activities, IVIG has been evaluated as a
therapeutic and preventive treatment for several infectious and
non-infectious conditions. Previous studies reported that IVIg
enhanced the bactericidal activity of serum by facilitating bacterial
opsonisation, neutralizing super antigens and toxins. IVIg also
modulates leukocytes by exerting a generalized anti-inﬂammatory
effect through its effects on Fc-receptor expression, complement,
cytokines, and B- and T-cells [17]. It has been suggested that the
application of IVIg in treatment of NSTI may result in a binding of
exotoxins produced by staphylococcal and streptococcal bacterial
infections and therefore in a limitation of systemic inﬂammatory
response [18,19]. In addition, antibodies targeting an unidentiﬁed
pathogen might have been present in IVIg, which helped to clear
the infection.
Neurologic and hematological disorders are the most common
indications for IVIg therapy. In this regard, hypogammaglobulin-
emia secondary to hematological malignancies, chronic inﬂam-
matory demyelinating polyneuropathy, and primary
immunodeﬁciency diseases remain the leading causes for IVIg use
[20]. Furthermore, Guillain-Barre syndrome, NF, and toxic
epidermal necrolysis are common indications for IVIg treatment in
critically ill patients at ICU [21].
Retrospective studies reported efﬁcient use of IVIg in the
treatment of NF, and the US Food and Drug Administration also
approved IVIg therapy for this indication. An observational cohort
study of 21 patients suffering from streptococcal toxic shock syn-
drome treated with IVIG revealed that IVIG increased the 30-day
survival rates to 67% compared to 34% in historical controls [22].
But unfortunately a double-blind, placebo-controlled trial that
searched for the beneﬁt of IVIG had to be terminated early due to
slow patient recruitment [23]. Recent randomized controlled trials,
however did not conﬁrm these retrospective data [24]. Other au-
thors suggested that IVIg use in patients suffering from NF should
be restricted to necrotizing soft tissue infections of either staphy-
lococcal or streptococcal origin because IVIg's mechanisms of ac-
tion might be based on exotoxin-IVIg binding [20,25]. IVIg therapy
is generally well tolerated and seems to provide a good safety
proﬁle. Beside potential risks associated with all blood products,
non-infectious reactions including systemic symptoms (headache,
back pain, nausea, and vomiting), renal failure, single cases of-reactive protein, CRP (mg/l) and white blood cell count, WBC (giga/l) during intensive
: Absolute values of procalcitonin, PCT (mg/l) and norepinephrine dose, NE (mg/min) as
arrow indicates the initiation of immunogloblin treatment (IVIg).
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tion, and retinal vein occlusion are described [21].
Nevertheless, currently there is no reliable data to generally
recommend the use of IVIg in NF. The current literature supporting
the use of IVIG in NF is largely based on retrospective or case-
controlled studies, and only small randomized trials [20e22].
Regarding recent data, further randomized controlled trials are
needed to recommend the brought use of IVIG for the treatment of
NF.
4. Conclusion
The demonstrated case suggests that IVIg treatment of patients
with NF can be considered in case of hemodynamic unstable, crit-
ically ill patients. Although randomized controlled trials are
missing, some patients might beneﬁt from diminishing hyper-
inﬂammation by immunoglobins.
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